These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21699947)

  • 21. Is there a link between MMR vaccine and autism?...and an expert's commentary.
    Child Health Alert; 2002 Dec; 20():1-2. PubMed ID: 12523275
    [No Abstract]   [Full Text] [Related]  

  • 22. MMR vaccine and idiopathic thrombocytopaenic purpura.
    Black C; Kaye JA; Jick H
    Br J Clin Pharmacol; 2003 Jan; 55(1):107-11. PubMed ID: 12534647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A population-based study of measles, mumps, and rubella vaccination and autism.
    Madsen KM; Hviid A; Vestergaard M; Schendel D; Wohlfahrt J; Thorsen P; Olsen J; Melbye M
    N Engl J Med; 2002 Nov; 347(19):1477-82. PubMed ID: 12421889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.
    Klein NP; Fireman B; Yih WK; Lewis E; Kulldorff M; Ray P; Baxter R; Hambidge S; Nordin J; Naleway A; Belongia EA; Lieu T; Baggs J; Weintraub E;
    Pediatrics; 2010 Jul; 126(1):e1-8. PubMed ID: 20587679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.
    Schink T; Holstiege J; Kowalzik F; Zepp F; Garbe E
    Vaccine; 2014 Feb; 32(6):645-50. PubMed ID: 24374498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases.
    Svanström H; Callréus T; Hviid A
    Drug Saf; 2010 Nov; 33(11):1015-25. PubMed ID: 20925439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak.
    Abedi GR; Mutuc JD; Lawler J; Leroy ZC; Hudson JM; Blog DS; Schulte CR; Rausch-Phung E; Ogbuanu IU; Gallagher K; Kutty PK
    Vaccine; 2012 Nov; 30(49):7052-8. PubMed ID: 23041123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales.
    Sonnenberg P; Crowcroft NS; White JM; Ramsay ME
    Arch Dis Child; 2007 Sep; 92(9):786-9. PubMed ID: 17412744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timely versus delayed early childhood vaccination and seizures.
    Hambidge SJ; Newcomer SR; Narwaney KJ; Glanz JM; Daley MF; Xu S; Shoup JA; Rowhani-Rahbar A; Klein NP; Lee GM; Nelson JC; Lugg M; Naleway AL; Nordin JD; Weintraub E; DeStefano F
    Pediatrics; 2014 Jun; 133(6):e1492-9. PubMed ID: 24843064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination.
    Patja A; Paunio M; Kinnunen E; Junttila O; Hovi T; Peltola H
    J Pediatr; 2001 Feb; 138(2):250-4. PubMed ID: 11174624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil.
    Freitas DR; Moura E; Araújo G; Cardoso A; Scheidt P; Ferraz E; Madalosso G; Chen RT; Hatch DL
    Vaccine; 2013 Jan; 31(6):950-4. PubMed ID: 23246259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N; Jansson UB; Alm B
    Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased emergency room visits or hospital admissions in females after 12-month MMR vaccination, but no difference after vaccinations given at a younger age.
    Wilson K; Ducharme R; Ward B; Hawken S
    Vaccine; 2014 Feb; 32(10):1153-9. PubMed ID: 24440113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine administration and the development of immune thrombocytopenic purpura in children.
    Cecinati V; Principi N; Brescia L; Giordano P; Esposito S
    Hum Vaccin Immunother; 2013 May; 9(5):1158-62. PubMed ID: 23324619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination associated thrombocytopenic purpura in children.
    Rajantie J; Zeller B; Treutiger I; Rosthöj S;
    Vaccine; 2007 Feb; 25(10):1838-40. PubMed ID: 17126957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.